Suresh Durgam, MD

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

August 25, 2025

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.

Suresh Durgam, Willie R. Earley, Susan G. Kozauer, et al

Original Research

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

April 24, 2023

Lumateperone significantly improved depression symptoms, disease severity, and quality of life in patients with bipolar depression with mixed features.

Stephen M. Stahl, Roger S. McIntyre, Suresh Durgam, et al

Original Research

NNT, NNH, and LHH for Lumateperone

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.

Leslie Citrome, Suresh Durgam, John B. Edwards, et al

Original Research

Vilazodone in Generalized Anxiety Disorder

December 28, 2016

The worries that characterize generalized anxiety disorder are so pervasive and excessive that they distort cognition and create a considerable burden of illness. See what the authors of this...

David V. Sheehan, Suresh Durgam, Maju Mathews, et al

Article

Vilazodone and Psychic and Somatic Anxiety

April 28, 2016

Is the SSRI vilazodone effective for treating generalized anxiety disorder? To comprehensively evaluate the effect of vilazodone across the range of anxiety symptoms associated with the disorder, Khan and...

Arif Khan, Suresh Durgam, Adam Ruth, et al

Original Research

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder

March 23, 2016

Maurizio Fava, Stuart A. Montgomery, Suresh Durgam, et al

Original Research

The Effect of Cariprazine on Hostility Associated With Schizophrenia: Post Hoc Analyses From 3 Randomized Controlled Trials

January 27, 2016

Leslie Citrome, Suresh Durgam, Kaifeng Lu, et al

Original Research

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

December 23, 2015

Herbert Y. Meltzer, Suresh Durgam, Andrew J. Cutler, et al

Original Research

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

November 25, 2014

Joseph R. Calabrese, Suresh Durgam, Kaifeng Lu, et al

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

NNT, NNH, and LHH for Lumateperone

Vilazodone in Generalized Anxiety Disorder

Vilazodone and Psychic and Somatic Anxiety

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder

The Effect of Cariprazine on Hostility Associated With Schizophrenia: Post Hoc Analyses From 3 Randomized Controlled Trials

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

ELSEWHERE:

FOLLOW US:

Suresh Durgam, MD

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

Efficacy of Lumateperone in Bipolar Depression With Mixed Features

NNT, NNH, and LHH for Lumateperone

Vilazodone in Generalized Anxiety Disorder

Vilazodone and Psychic and Somatic Anxiety

Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder

The Effect of Cariprazine on Hostility Associated With Schizophrenia: Post Hoc Analyses From 3 Randomized Controlled Trials

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles